Fighting Infectious Diseases in Emerging Countries

Recent papers from Fighting Infectious Diseases in Emerging Countries

1. Effect of inactivated poliovirus vaccine on nasal mucosal immunity and pharyngeal shedding following novel oral poliovirus vaccine type 2 challenge: A randomized, open-label trial.2026
2. HPV burden in Armenia among unvaccinated women: a series of cross-sectional population-based prevalence surveysVaccine · 2025
3. Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trialsThe Lancet Microbe · 2025
4. Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Vaccinated Children and Vaccine-Naïve Infants: A Phase 4 StudyVaccines · 2024
5. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican RepublicThe Lancet Infectious Diseases · 2023
6. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trialsThe Lancet Microbe · 2022
7. Investigating the therapeutic options for diabetes‐associated male infertility as illustrated in animal experimental modelsAndrologia · 2022
8. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in childrennpj Vaccines · 2022
9. Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical TrialsThe Journal of Infectious Diseases · 2021
10. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine virusesnpj Vaccines · 2021
11. Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in PanamaViruses · 2021
12. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trialsThe Lancet · 2020
13. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trialThe Lancet Infectious Diseases · 2020
14. A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in LithuaniaThe Journal of Infectious Diseases · 2020
15. Direct Comparison of Pneumatic and Ho:YAG Laser Lithotripsy in the Management of Lower Ureteric StonesUrologia Internationalis · 2020
16. Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication EndgameClinical Infectious Diseases · 2018
17. Quantitative multiplex one-step RT-PCR assay for identification and quantitation of Sabin strains of poliovirus in clinical and environmental specimensJournal of Virological Methods · 2018
18. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedulesVaccine · 2017
19. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infantsThe Lancet Infectious Diseases · 2016